F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, vol.68, issue.6, pp.394-424, 2018.

G. Fattovich, T. Stroffolini, I. Zagni, and F. Donato, Hepatocellular carcinoma in cirrhosis: incidence and risk factors, Gastroenterology, vol.127, issue.5, pp.35-50, 2004.

P. Bertuccio, F. Turati, G. Carioli, T. Rodriguez, L. Vecchia et al., Global trends and predictions in hepatocellular carcinoma mortality, J Hepatol, vol.67, issue.2, pp.302-311, 2017.

M. Anzola, Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis, J Viral Hepat. sept, vol.11, issue.5, pp.383-93, 2004.

S. S. Thorgeirsson and J. W. Grisham, Molecular pathogenesis of human hepatocellular carcinoma, Nat Genet. août, vol.31, issue.4, pp.339-385, 2002.

, The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global

J. A. Flemming, J. D. Yang, E. Vittinghoff, W. R. Kim, and N. A. Terrault, Risk prediction of hepatocellular carcinoma in patients with cirrhosis: The ADRESS-HCC risk model: The ADRESS-HCC Risk Model, Cancer, vol.120, issue.22, pp.3485-93, 2014.

A. Moro, J. Jiang, M. Gigou, and C. Féray, Carcinogenèse hépatique et virus de l'hépatite C. médecine/sciences. mars, vol.18, pp.335-377, 2002.

G. A. Heckley, J. Jarl, B. O. Asamoah, G. -gerdtham, and U. , How the risk of liver cancer changes after alcohol cessation: a review and meta-analysis of the current literature, BMC Cancer, vol.11, p.446, 2011.

C. Desbois-mouthon, De la stéatohépatite non alcoolique au carcinome hépatocellulaire : mécanismes physiopathologiques, Médecine Mal Métaboliques. févr, vol.5, issue.1, pp.38-44, 2011.

B. Zhang, Y. Tang, and Z. , Randomized controlled trial of screening for hepatocellular carcinoma, J Cancer Res Clin Oncol. juill, vol.130, issue.7, pp.417-439, 2004.

L. Bolondi, Screening for hepatocellular carcinoma in cirrhosis, J Hepatol. 1 déc, vol.39, issue.6, pp.1076-84, 2003.

A. Singal, M. L. Volk, A. Waljee, R. Salgia, P. Higgins et al., Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis, Aliment Pharmacol Ther. juill, vol.30, issue.1, pp.37-47, 2009.

J. A. Marrero, Z. Feng, Y. Wang, M. H. Nguyen, A. S. Befeler et al., Des-? Carboxyprothrombin, and Lectin-Bound ?-Fetoprotein in Early Hepatocellular Carcinoma, vol.137, pp.110-118, 2009.

K. L. Andersson, J. A. Salomon, S. J. Goldie, and R. T. Chung, Cost Effectiveness of Alternative Surveillance Strategies for Hepatocellular Carcinoma in Patients With Cirrhosis, Clin Gastroenterol Hepatol. déc, vol.6, issue.12, pp.1418-1442, 2008.

T. Akinyemiju, S. Abera, M. Ahmed, N. Alam, and M. A. Alemayohu, The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study, JAMA Oncol. 1 déc, vol.3, issue.12, p.1683, 2015.

, Novel advancements in the management of hepatocellular carcinoma in 2008

D. Sur,

A. Colli, M. Fraquelli, G. Casazza, S. Massironi, A. Colucci et al., Accuracy of Ultrasonography, Spiral CT, Magnetic Resonance, and Alpha-Fetoprotein in Diagnosing Hepatocellular Carcinoma: A Systematic Review. CME, Am J Gastroenterol. mars, vol.101, issue.3, pp.513-536, 2006.

, Place de la radiofréquence dans la destruction des tumeurs du foie

P. Compagnon, S. Grandadam, R. Lorho, B. Turlin, C. Camus et al., Liver Transplantation for Hepatocellular Carcinoma Without Preoperative Tumor Biopsy: Transplantation, vol.86, pp.1068-76, 2008.

G. D'amico, G. Garcia-tsao, and L. Pagliaro, Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies, J Hepatol. janv, vol.44, issue.1, pp.217-248, 2006.

C. Duvoux, F. Roudot-thoraval, T. Decaens, F. Pessione, H. Badran et al., Liver transplantation for hepatocellular carcinoma: a model including ?-fetoprotein improves the performance of Milan criteria, Gastroenterology, vol.143, issue.4, pp.986-994, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00865368

J. Bruix and M. Sherman, Management of hepatocellular carcinoma: An update, Hepatology. mars, vol.53, issue.3, pp.1020-1022, 2011.

L. Rimassa and A. Santoro, Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial, Expert Rev Anticancer Ther. juin, vol.9, issue.6, pp.739-784, 2009.

A. Cheng, Y. Kang, Z. Chen, C. Tsao, S. Qin et al., Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, Lancet Oncol. janv, vol.10, issue.1, pp.25-34, 2009.

M. Kudo, R. S. Finn, S. Qin, K. Han, K. Ikeda et al., Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial, The Lancet. mars, vol.391, pp.1163-73, 2018.

J. Bruix, S. Qin, M. P. Granito, A. Huang, Y. Bodoky et al., Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Lond Engl, vol.07, pp.56-66, 2017.

G. K. Abou-alfa, T. Meyer, A. Cheng, A. B. El-khoueiry, L. Rimassa et al., Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma, N Engl J Med. 5 juill, vol.379, issue.1, pp.54-63, 2018.

. Référentiel-«carcinome-hépatocellulaire, CHC)

, Anatomie du foie -Cancer du foie

V. Vilgrain, M. Vullierme, M. Djabbari, A. Sibert, and Y. Menu, Foie et anomalies de perfusion en imagerie, vol.12, 2020.

J. Cazejust, B. Bessoud, N. Colignon, C. Garcia-alba, O. Planché et al., Hepatocellular carcinoma vascularization: From the most common to the lesser known arteries, Diagn Interv Imaging. janv, vol.95, issue.1, pp.27-36, 2014.

A. X. Zhu, D. G. Duda, D. V. Sahani, and R. K. Jain, HCC and angiogenesis: possible targets and future directions, Nat Rev Clin Oncol. mai, vol.8, issue.5, pp.292-301, 2011.

. Ct-14331_lipiodol_ultra_fluide_pic_ei_avispostobs_ct14331.pdf.-disponible and . Sur,

F. Piscaglia and S. Ogasawara, Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment, Liver Cancer, vol.7, issue.1, pp.104-123, 2018.

, Traitement des tumeurs malignes du foie par radiologie interventionnelle : techniques intra-artérielles -Revue Médicale Suisse

D. Sur,

J. Wolff, Physiology and pharmacology of iodized oil in goiter prophylaxis, Medicine (Baltimore). janv, vol.80, issue.1, pp.20-36, 2001.

J. L. Raoul, P. Bourguet, J. F. Bretagne, R. Duvauferrier, S. Coornaert et al., Hepatic artery injection of I-131-labeled lipiodol. Part I. Biodistribution study results in patients with hepatocellular carcinoma and liver metastases, Radiology. août, vol.168, issue.2, pp.541-546, 1988.

, Résumé des caractéristiques du produit -LIPIODOL ULTRA-FLUIDE 480 mg/ml, solution injectable -Base de données publique des médicaments

R. C. Gaba, R. M. Schwind, and S. Ballet, Mechanism of Action, Pharmacokinetics, Efficacy, and Safety of Transarterial Therapies Using Ethiodized Oil: Preclinical Review in Liver Cancer Models, J Vasc Interv Radiol JVIR, vol.29, issue.3, pp.413-437, 2018.

Z. Kan, P. A. Mccuskey, K. C. Wright, and S. Wallace, Role of Kupffer cells in iodized oil embolization. Invest Radiol, vol.29, pp.990-993, 1994.

T. De-baere, Y. Arai, R. Lencioni, J. Geschwind, W. Rilling et al., Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion, Cardiovasc Intervent Radiol. mars, vol.39, issue.3, pp.334-377, 2016.

R. A. Sheth, S. Sabir, S. Krishnamurthy, R. K. Avery, Y. S. Zhang et al., Endovascular Embolization by Transcatheter Delivery of Particles: Past, Present, and Future, J Funct Biomater. 3 avr, vol.8, issue.2, p.12, 2017.

M. Boulin, E. Delhom, M. Pierredon-foulongne, J. Cercueil, and B. Guiu, Chimioembolisation des carcinomes hépatocellulaires : une vieille méthode au goût du jour, J Radiol Diagn Interv. juin, vol.96, issue.2, pp.162-71, 2015.

M. Boulin, E. Delhom, M. Pierredon-foulongne, J. Cercueil, and B. Guiu, Chimioembolisation des carcinomes hépatocellulaires : une vieille méthode au goût du jour, 2015.

D. Sur,

T. De-baere, X. Zhang, A. B. Harry, G. Lagrange, C. Ropers et al., Quantification of tumor uptake of iodized oils and emulsions of iodized oils: experimental study, Radiology. déc, vol.201, issue.3, pp.731-736, 1996.

H. Nakamura, T. Hashimoto, H. Oi, and S. Sawada, Transcatheter oily chemoembolization of hepatocellular carcinoma, Radiology. mars, vol.170, issue.3, pp.783-789, 1989.

T. De-baere, J. Dufaux, A. Roche, J. L. Counnord, M. F. Berthault et al., Circulatory alterations induced by intra-arterial injection of iodized oil and emulsions of iodized oil and doxorubicin: experimental study, Radiology. janv, vol.194, issue.1, pp.165-70, 1995.

K. Takayasu, S. Arii, I. Ikai, M. Kudo, Y. Matsuyama et al., Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis, AJR Am J Roentgenol. mars, vol.194, issue.3, pp.830-837, 2010.

K. Takayasu, Y. Shima, Y. Muramatsu, N. Moriyama, T. Yamada et al., Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents, Radiology. mai, vol.163, issue.2, pp.345-51, 1987.

C. Lo, Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma, Hepatology. mai, vol.35, issue.5, pp.1164-71, 2002.

, A Comparison of Lipiodol Chemoembolization and Conservative Treatment for Unresectable Hepatocellular Carcinoma, N Engl J Med. 11 mai, vol.332, pp.1256-61, 1995.

J. Raoul, B. Sangro, A. Forner, V. Mazzaferro, F. Piscaglia et al., Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization, Cancer Treat Rev. mai, vol.37, issue.3, pp.212-232, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01134844

J. Idée and B. Guiu, Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: A review, Crit Rev Oncol Hematol. déc, vol.88, issue.3, pp.530-579, 2013.

F. Somma, R. Angelo, N. Serra, G. Gatta, R. Grassi et al., Use of Ethanol in the Trans-Arterial Lipiodol Embolization (TAELE) of Intermediated-Stage HCC: Is This Safer than Conventional Trans-Arterial Chemo-Embolization (c-TACE)?, PloS One, vol.10, issue.6, p.129573, 2015.

F. Mohné, C. Meyer, C. K. Kuhl, C. C. Pieper, and H. H. Schild, Transarterial Alcohol-Lipiodol Therapy in Patients with Hepatocellular Carcinoma Using Low Alcohol Concentrations, ROFO Fortschr Geb Rontgenstr Nuklearmed. juill, vol.188, issue.7, pp.676-83, 2016.

S. Yu, J. Hui, E. P. Hui, F. Mo, P. Lee et al., Embolization efficacy and treatment effectiveness of transarterial therapy for unresectable hepatocellular carcinoma: a case-controlled comparison of transarterial ethanol ablation with lipiodolethanol mixture versus transcatheter arterial chemoembolization, J Vasc Interv Radiol JVIR. mars, vol.20, issue.3, pp.352-361, 2009.